Karyopharm Therapeutics | KPTI - Net Income


Karyopharm Therapeutics reported $-30.78M in Net Income for its fiscal quarter ending in December of 2024.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Abbott USD 1.78B 132M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 74.85M Dec/2024
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
J&J USD 5.12B 36M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
MacroGenics USD 16.82M 53.07M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Nektar Therapeutics USD -37.06M 15.31M Sep/2024
Novartis USD 3.93B 96M Sep/2025
Novartis USD 3.93B 113M Sep/2025
Pfizer USD -1.65B 5.19B Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Takeda JPY 103.64B 115.44B Dec/2025
Tectonic Therapeutic USD -19.04M 940K Sep/2025
TG Therapeutics USD 390.9M 362.71M Sep/2025
Ultragenyx Pharmaceutical USD -180.41M 65.46M Sep/2025
Xencor USD -6.03M 24.8M Sep/2025